article thumbnail

Sygnature Discovery acquires Peak Proteins

Sygnature Discovery

Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of protein production and related structure determination projects within Sygnature. The Peak Proteins leadership team will also remain with the business.

article thumbnail

Key considerations before commencing cell line development

Drug Target Review

5 And for the latter, the development of a technique to temporally track gene expression in CHO cells, which therefore has the potential to lead to the identification of targets to improve recombinant protein production. 2016), 32: 1301-1307 Matasci M, Baldo L, et al. 2007), 103(7): 40–47. Rajendra Y, Peery RB, Barnard GC.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering: A Next-Generation Medium Sized Molecular Biotechnology-Based Drug Discovery Firm

The Pharma Data

Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using protein production technology such as enzymes cultivated by our technology. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund] “Proteins are an important structural component of living things.

article thumbnail

Beyond Steel Tanks

Codon

In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease. In 2016, a company called Synageva BioPharma (formerly AviGenics) was acquired by Alexion for $8.4B. Tiamat Sciences harvests a variety of protein products in tobacco plants.

article thumbnail

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

” About Elasmogen: Spun-out from the University of Aberdeen, Scotland in 2016, Elasmogen is developing soloMERs ; fully humanized (or de-immunised) VNAR, as next generation, single chain therapeutics for auto-inflammatory diseases, oncology and intracellular delivery.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Philosophical Transactions of the Royal Society B (2016). Link →A Brief History of De Novo Protein Design: Minimal, Rational, and Computational , by Woolfson D.N. Link The coming of age of de novo protein design , by Huang P-S. Nature (2016). Science (2016). Nature (2016). & Charpentier E.

DNA 91
article thumbnail

The Codon Guide to Synthetic Biology

Codon

Philosophical Transactions of the Royal Society B (2016). Link →A Brief History of De Novo Protein Design: Minimal, Rational, and Computational , by Woolfson D.N. Link The coming of age of de novo protein design , by Huang P-S. Nature (2016). Science (2016). Nature (2016). Cell (2016).

DNA 52